At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 476 enrolled
Drug / intervention
Empagliflozin 10 mg +1 moredrug
Likely dose
Empagliflozin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
In Brief
A Phase 3 clinical trial evaluating Empagliflozin 10 mg and Placebo Oral Tablet for Acute Myocardial Infarction. Completed, enrolled 476 participants across 11 sites.
Detailed Summary
This study is planned to investigate the impact of Empagliflozin on biomarkers of heart failure in patients with myocardial infarction with and without type 2 diabetes mellitus within 6 months after the event.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myocardial Infarction
CountriesAustria
CollaboratorsUnited Arab Emirates University, Medical University of Vienna, Landeskrankenhaus Feldkirch, Paracelsus Medical University, Hospital Rudolfstiftung, Klinikum Klagenfurt am Wörthersee, Barmherzige Brüder Eisenstadt, Cardinal Schwarzenberg Hospital, Johannes Kepler University of Linz, Landesklinikum Sankt Polten, Landeskrankenhaus II Graz West
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartMay 2017
Primary CompletionMay 2022
Study CompletionMay 2022
TodayJul 2026
First PostedMar 23, 2017
Enrollment StartMay 11, 2017
Primary CompletionMay 3, 2022
Study CompletionMay 17, 2022
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 9.3 years ago
Interventions
Empagliflozin 10 mgdrug
The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.
Placebo Oral Tabletdrug
The subject will receive Placebo orally once daily for 26 weeks.